Treatment of mycosis fungoides and Sézary syndrome: recent advances and novel therapies

References

• Willemze R, Kerl H, Sterry W et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood90, 354–371 (1997).
   PubMed Web of Science ®Google Scholar
• Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood105, 3768–3785 (2005).
   PubMed Web of Science ®Google Scholar
• Slater DN. The new World Health Organization-European Organization for Research and Treatment of cancer classification for cutaneous lymphomas: a practical marriage of two giants. Br. J. Dermatol.153(5), 874–880 (2005).
   PubMed Web of Science ®Google Scholar
• Zackheim HS, Amin S, Kashani-Sabet M, McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J. Am. Acad. Dermatol.40, 418–425 (1999).
   PubMed Web of Science ®Google Scholar
• Trautinger F, Knobler R, Willemze R et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur. J. Cancer42(8), 1014–1030 (2006).
   PubMed Web of Science ®Google Scholar
• Querfeld C, Rosen ST, Guitart J, Kuzel TM. The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy. Curr. Opin. Hematol.12(4), 273–278 (2005).
   PubMedGoogle Scholar
• Whittaker SJ. Joint BAD & UKCLG guidelines for CTCL. Br. J. Dermatol.149, 1095–1107 (2003).
   PubMed Web of Science ®Google Scholar
• Bunn PA Jr, Lamberg SI. Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat. Rep.63, 725–728 (1979).
   PubMedGoogle Scholar
• Scarisbrick JJ, Whittaker S, Evans AV et al. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood97, 624–630 (2001).
   PubMed Web of Science ®Google Scholar
• Fraser-Andrews EA, Woolford AJ, Russell-Jones R et al. Detection of a peripheral blood T cell clone is an independent prognostic marker in mycosis fungoides. J. Invest. Dermatol.114, 117–121 (2000).
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Marsden JR, Spittle M, Russell Jones R; British Association of Dermatologists; U.K. Cutaneous Lymphoma Group. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br. J. Dermatol.149, 1095–1107 (2003).
   PubMed Web of Science ®Google Scholar
• Kaye FJ, Bunn PA Jr, Steinberg SM et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N. Engl. J. Med.321, 1784–1790 (1989).
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ. The staging and management of cutaneous T-cell lymphomas. Clin. Exp. Dermatol.31, 181–186 (2006).
   PubMed Web of Science ®Google Scholar
• Knobler E. Current management strategies for cutaneous T-cell lymphoma. Clin. Dermatol.22(3), 197–208 (2004).
   PubMed Web of Science ®Google Scholar
• Prince HM, McCormack C, Ryan G et al. Management of the primary cutaneous lymphomas. Australas. J. Dermatol.44(4), 227–240 (2003).
   PubMedGoogle Scholar
• Hoppe RT, Abel EA, Deneau DG, Price NM. Mycosis fungoides: management with topical nitrogen mustard. J. Clin. Oncol.5, 1796–1803 (1987).
   PubMed Web of Science ®Google Scholar
• Breneman D, Duvic M, Kuzel T et al. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch. Dermatol.138(3), 325–332 (2002).
   PubMed Web of Science ®Google Scholar
• Deeths MJ, Chapman JT, Dellavalle RP et al. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J. Am. Acad. Dermatol.52(2), 275–280 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenbaum MM, Roenigk HH Jr, Caro WA, Esker A. Photochemotherapy in cutaneous T cell lymphoma and parapsoriasis en plaques. Long-term follow-up in forty-three patients. J. Am. Acad. Dermatol.13, 613–622 (1985).
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Child FJ, Evans AV et al. Secondary malignant neoplasms in 71 patients with Sézary syndrome. Arch. Dermatol.135, 1381–1385 (1999).
   PubMed Web of Science ®Google Scholar
• Diederen PV, Van Weelden H, Sanders CJ, et al. Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study. J. Am. Acad. Dermatol.48, 215–219 (2003).
   PubMed Web of Science ®Google Scholar
• Hoppe RT. Total skin electron beam therapy in the management of mycosis fungoides. Front Radiat. Ther. Oncol.25, 132–133 (1991).
   Google Scholar
• Dummer R, Heald PW, Nestle FO et al. Sézary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-γ receptor β-chain). Blood88(4), 1383–1389 (1996).
   PubMed Web of Science ®Google Scholar
• Olsen EA, Rosen ST, Vollmer RT et al. Interferon α-2a in the treatment of cutaneous T cell lymphoma. J. Am. Acad. Dermatol.20, 395–407 (1989).
   PubMed Web of Science ®Google Scholar
• Bunn PA Jr, Ihde DC, Foon KA. The role of recombinant interferon α-2a in the therapy of cutaneous T-cell lymphomas. Cancer57, 1689–1695 (1986).
   PubMed Web of Science ®Google Scholar
• Roenigk HH Jr, Kuzel TM, Skoutelis AP et al. Photochemotherapy alone or combined with interferon-2α in the treatment of cutaneous T-cell lymphoma. J. Invest. Dermatol.95, S198–S205 (1990).
   Web of Science ®Google Scholar
• Stadler R, Otte HG, Luger T et al. Prospective randomized multicenter clinical trial on the use of interferon-2α plus acitretin versus interferon-2α plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood92(10), 3578–3581 (1998).
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Sasaki G, Sato T, Katayama I, Nishioka K. Cytokine profile of tumor cells in mycosis fungoides: successful treatment with intra-lesional interferon-γ combined with chemotherapy. J. Dermatol.22(9), 650–654 (1999).
   Google Scholar
• Dummer R, Hassel JC, Fellenberg F et al. Adenovirus-mediated intralesional interferon-γ gene transfer induces tumor regressions in cutaneous lymphomas. Blood104(6), 1631–1638 (2004).
   PubMed Web of Science ®Google Scholar
• Nichols J, Foss F, Kuzel TM et al. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur. J. Cancer33, S34–S36 (1997).
   PubMed Web of Science ®Google Scholar
• Lundin J, Osterborg A, Brittinger G et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin’s lymphomas: a Phase II multicenter study. European Study Group of CAMPATH-1H treatment in low-grade non-Hodgkin’s lymphoma. J. Clin. Oncol.16, 3257–3263 (1998).
   PubMed Web of Science ®Google Scholar
• Zhang C, Duvic M. Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma. Dermatol. Ther.16(4), 322–330 (2003).
   PubMedGoogle Scholar
• Talpur R, Ward S, Apisarnthanarax N et al. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J. Am. Acad. Dermatol.47, 672–684 (2002).
   PubMed Web of Science ®Google Scholar
• Duvic M, Martin AG, Kim Y et al. Phase II and III clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch. Dermatol.137, 581–593 (2001).
   PubMed Web of Science ®Google Scholar
• Edelson R, Berger C, Gasparro F et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N. Engl. J. Med.316, 297–303 (1987).
   PubMed Web of Science ®Google Scholar
• Gottlieb SL, Wolfe JT, Fox FE et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon-α: a 10-year experience at a single institution. J. Am. Acad. Dermatol.35, 946–957 (1996).
   PubMed Web of Science ®Google Scholar
• Child FJ, Mitchell TJ, Whittaker SJ et al. A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clin. Exp. Dermatol.29, 231–236 (2004).
   PubMed Web of Science ®Google Scholar
• Bunn PA Jr, Hoffman SJ, Norris D et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Ann. Intern. Med.121, 592–602 (1994).
   PubMed Web of Science ®Google Scholar
• Kaye FJ, Bunn PA Jr, Steinberg SM et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N. Engl. J. Med.321, 1784–1790 (1989).
   PubMed Web of Science ®Google Scholar
• Bigler RD, Crilley P, Micaily B et al. Autologous bone marrow transplantation for advanced stage mycosis fungoides. Bone Marrow Transplant.7(2), 133–137 (1991).
   Google Scholar
• Olavarria E, Child F, Woolford A et al. T-cell depletion and autologous stem cell transplantation in the management of tumor stage mycosis fungoides with peripheral blood involvement. Br. J. Haematol.114(3), 624–631 (2001).
   PubMed Web of Science ®Google Scholar
• Molina A, Zain J, Arber DA et al. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sézary syndrome and mycosis fungoides. J. Clin. Oncol.23, 6163–6171 (2005).
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Zhang C, Goy A, Richon V, Frankel SR. Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) unresponsive to conventional therapy. J. Clin. Oncol.S16, 6571 (2005) (Abstract).
   Google Scholar
• Piekarz RL, Robey R, Sandor V et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood98, 2865–2868 (2001).
   PubMed Web of Science ®Google Scholar
• Piekarz R, Jewell S, Bakke S et al. Cardiac effects of depsipeptide, FK228, in patients with T-cell lymphoma. Proc. Am. Soc. Clin. Oncol.22, 201 (Abstract 806).
   Google Scholar
• Wysocka M, Benoit BM, Newton S et al. Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. Blood104(13), 4142–4149 (2004).
   PubMed Web of Science ®Google Scholar
• Querfeld C, Rosen ST, Guitart J, Kuzel TM. The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy. Curr. Opin. Hematol.12(4), 273–278 (2005).
   PubMedGoogle Scholar